Topic

Articles

FDA has approved Regeneron Pharmaceuticals’ Eylea (aflibercept), an anti-vascular endothelial growth factor inhibitor, to treat four retinal conditions.

FDA Approves Regeneron’s Eylea for Eye Disease

The new drug is meant to be used in combination therapy for treating pediatric patients with pulmonary multidrug-resistant tuberculosis.

FDA Grants Accelerated Approval to Janssen’s Tuberculosis Drug

FDA has approved Roche’s new cancer drug for treating metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumors and neurotrophic tyrosine receptor kinase gene fusion-positive solid tumors.

FDA Approves Roche’s New Cancer Drug

Cannuba has announced its support of the first national pilot study in the United Kingdom aimed at assessing patients on prescription medical cannabis.

Cannuba Supports UK’s First National Pilot Study on Medical Cannabis

The companies have signed a strategic multi-year manufacturing agreement for the future commercial production a late-phase investigational cell therapy.

Lonza, Gamida Cell Form Commercial Cell-Therapy Manufacturing Pact

The acquisition will boost Merck’s pipeline for cancer, fibrosis, and autoimmune disease therapeutics.

Merck & Co. to Acquire Tilos Therapeutics in Deal Worth Up to $773 Million

MilliporeSigma awarded its Advance Biotech Grant to three US companies that are focused on traumatic brain injury, vaccine development, and chronic pain.

MilliporeSigma Announces North America Biotech Award Winners

The agency says Novartis drug is the first PI3K inhibitor to be approved for treating breast cancer.

FDA Approves Novartis’ PI3K Inhibitor for Breast Cancer

The acquisition provides Valby, Denmark-based Lundbeck with a discovery platform and a US-based research hub.

Lundbeck to Acquire Abide Therapeutics

The acquisition will expand Pfizer’s rare disease portfolio with an early pipeline candidate for treating dwarfism.

Therapeutic-Specific Areas